Investing.com - Pear Therapeutics reported on Monday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Pear Therapeutics...
Pear Therapeutics (PEAR) reported Q3 EPS of ($0.22), $0.01 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $4.1 million versus the consensus estimate...
Pear Therapeutics (PEAR) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.7 million versus the consensus...
Pre-Open Stock Movers: NeoGenomics, Inc. (NASDAQ:NEO) 29% LOWER; CEO Mark Mallon to step down. Expects revenue for Q1 2022 may be below the low end of its prior guidance of $118 -...
Pear Therapeutics Inc (NASDAQ:PEAR) reported Q4 EPS of $0.13, $0.54 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $1.32 million versus the...
Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics...
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and...